Page 138 - Drug Class Review

Page 99 of 205
Drug Effectiveness Review Project
treatment in excess of that for placebo treatment was 9% (95% CI: 6% – 10%) excluding one study because
unspecified QOL scale, IDDD; global response defined as improved on a global assessment scale (CGIC or
Global responders extracted from 9 studies: pooled mean proportion of global responders to ChE inhibitor
DON 1-10 mg/d given for 12-54 weeks; RIV 1-12 mg/d given for 13-26 weeks; GAL 8-36 mg/d given for
CIBIC plus) and cognitive responders were defined as subjects with a 4-point or greater improvement in
3-6 months; outcome measures included CGIC; CIBIC; ADAS-Cog, MMSE, NPI, DAD, FRS, PDS,
of heterogeneity; proportion of cognitive responders could be extracted from 5 studies: pooled mean

10% (95% CI: 4% – 17%) proportion of cognitive responders to ChE inhibitor treatment in excess of that for placebo treatment was Compared with those receiving placebo, significantly more subjects receiving ChE inhibitor treatment had adverse advents (8%) (95% CI: 5% – 11%), dropped out (8%) (95% CI: 5% – 11%) and dropped out because of adverse events (7%) (95% CI: 3% – 10%) MEDLINE and EMBASE searches from January 1980 to May 2002; key words ChE inhibitor and AD, and the limits were RCT, English and human; Cochrane library also searched Trials included if t

ADAS-Cog meta analysis Good

Final Report Update 1 Authors: Lanctot et al. Year: 2003 CHARACTERISTICS OF INTERVENTIONS: MAIN RESULTS: ADVERSE EVENTS: COMPREHENSIVE LITERATURE SEARCH STRATEGY: STANDARD METHOD OF APPRAISAL OF STUDIES: QUALITY RATING: Alzheimer's Drugs